vimarsana.com

Latest Breaking News On - Priteshj gandhi - Page 1 : vimarsana.com

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Massachusetts
United-states
Daniel-haber
Mehmet-toner
David-miyamoto
Shyamala-maheswaran
Annie-partisano
Priteshj-gandhi
Aditya-bardia
Telldx-technology-demonstrates-efficacy-of-novel-drug
Breast-cancer-research-program
Tellbio-inc

Circulating Tumor Cell (CTC) Isolation with TellDx

Single-cell proteomics can elucidate kinase activity in prostate cancer models Kinase activity in bone metastases and epithelial circulating.

Massachusetts
United-states
Priteshj-gandhi
Mehmet-toner
Daniela-haber
Shyamala-maheswaran
Annie-partisano
Cancer-research
Tellbio-inc
Hospital-center
Drs-david-ting
Massachusetts-general-hospital-center

BioSpace Movers & Shakers, May 14

Published: May 13, 2021 By Alex Keown Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. Prior to Spark, Reape was senior vice president of clinical development focusing on global brands research and development at Allergan and Actavis. CARMAT – France-based CARMAT’s board of directors is reorganizing its governance and appointed three new directors. The company tapped Florent Battistella, David Coti and John B. Hernandez as directors. Battistella founded Nisima, a holding company, which holds stakes in various firms, notably

Oslo
Norway
Toronto
Ontario
Canada
Texas
United-states
Quadrucept-bio
Vineet-agarwal
Janice-olson
Einaro-vik-mo
Kyle-chiang

TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

Published: May 10, 2021 Closes $5 million Series A financing Appoints Pritesh J. Gandhi, PharmD, as Chief Executive Officer and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations Announces exclusive license of TellDx platform to Genetron Holdings Limited for China Secures Deployment of TellDx at ARUP Laboratories, Inc BEVERLY, Mass., May 10, 2021 (GLOBE NEWSWIRE) TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and complementary therapeutics platform, TellRx, today announced the closing of a $5 million Series A financing. Concurrent with the close, the Company announced the appointments of Pritesh J. Gandhi, PharmD, as Chief Executive Officer (CEO) and Annie Partisano, PharmD, MS, as Senior Vice President and Head of Operations; an exclusive license of the TellDx platform to Genetron Holdi

China
United-states
University-of-massachusetts-medical-school
Massachusetts
Chinese
Ryo-imai
Sanofi-genzyme
Ravi-kapur
David-ting
Richard-peters
Priteshj-gandhi
Mehmet-toner

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.